The National Institute of Allergy and Infectious Diseases (NIAID) awarded Louisiana State University (LSU) a $715,216 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the role of the transcription factor Nrf2 in host defense against carbapenem-resistant Klebsiella pneumoniae (CRKP) infection. This 5-year research project (July 1, 2024 - May 31, 2029) aims to investigate how Nrf2 activation influences lung function, neutrophil activity, emergency granulopoiesis, and alveolar macrophage responses during CRKP-induced pneumonia and sepsis. The study will utilize in vivo mouse models and in vitro human cell cultures to elucidate the signaling cascades involved in the innate immune response to CRKP, with the goal of informing the development of improved therapies to enhance host defense and mitigate tissue damage from pneumonia-derived sepsis. This federally funded research project supports NIAID's broader efforts to advance the scientific understanding and treatment of infectious diseases, a persistent public health challenge.
Generated 2/25/25, 3:49 AM